Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Bristol Myers' first-quarter performance and raised annual guidance are encouraging. However, we recommend investors to stay on the sidelines as generic competition for legacy drugs and recent pipeline setbacks weigh on the stock.
Bristol-Myers Squibb's Q1 2025 results confirm that the stock has significant potential upside now. The company's Growth Portfolio showed healthy sales increase, while the non-GAAP EPS surprised positively, beating estimates by 20%. BMS upgraded its 2025 guidance a bit too, reducing expected revenue shrinkage to 4.1% and raising non-GAAP EPS expectations by 2.24%.
Drug Manufacturers - General Industry | Healthcare Sector | Dr. Christopher S. Boerner Ph.D. CEO | NYSE Exchange | US1101221083 ISIN |
Germany Country | - Employees | 4 Apr 2025 Last Dividend | 7 Aug 2001 Last Split | - IPO Date |
Bristol-Myers Squibb Company is an eminent global biopharmaceutical firm engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative biopharmaceutical products. With a spectrum of treatments covering hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases, the company has established a significant footprint in the healthcare sector. Initially founded as Bristol-Myers Company in 1887, it has evolved over the decades to become a leader in the biopharmaceutical industry, headquartered in Princeton, New Jersey. The company's operational reach spans globally, selling products through a diversified channel mix including wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.